Correction to: 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.

Writing Group Members* Craig T. January, MD, PhD, FACC (Chair), L. Samuel Wann, MD, MACC, FAHA (Vice Chair), Hugh Calkins, MD, FACC, FAHA, FHRS,* Lin Y. Chen, MD, MS, FACC, FAHA, FHRS, Joaquin E. Cigarroa, MD, FACC, Joseph C. Cleveland Jr., MD, FACC,*,x Patrick T. Ellinor, MD, PhD,* Michael D. Ezekowitz, MBChB, DPhil, FACC, FAHA,*,k Michael E. Field, MD, FACC, FAHA, FHRS,k Karen L. Furie, MD, MPH, FAHA,k Paul A. Heidenreich, MD, FACC, FAHA,{ Katherine T. Murray, MD, FACC, FAHA, FHRS,k Julie B. Shea, MS, RNCS, FHRS,*,k Cynthia M. Tracy, MD, FAHA,k Clyde W. Yancy, MD, MACC, FAHAk

[1]  V. Aboyans,et al.  Female sex as a risk factor for ischaemic stroke varies with age in patients with atrial fibrillation , 2019, Heart.

[2]  Correction to: Outcomes Associated with Apixaban Use in End-Stage Kidney Disease Patients with Atrial Fibrillation in the United States. , 2018, Circulation.

[3]  P. Noseworthy,et al.  Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States , 2018, Circulation.

[4]  S. Yusuf,et al.  Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. , 2018, Journal of the American College of Cardiology.

[5]  R. Mahajan,et al.  PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[6]  B. Lindsay,et al.  Smartwatch Algorithm for Automated Detection of Atrial Fibrillation. , 2018, Journal of the American College of Cardiology.

[7]  P. Kirchhof,et al.  Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial , 2018, European heart journal.

[8]  H. Maitland,et al.  Safety and effectiveness of apixaban compared to warfarin in dialysis patients , 2018, Research and practice in thrombosis and haemostasis.

[9]  R. de Caterina,et al.  Digoxin and Mortality in Patients With Atrial Fibrillation. , 2018, Journal of the American College of Cardiology.

[10]  D. Mark,et al.  Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design , 2018, American heart journal.

[11]  G. Lip,et al.  Prediction of long‐term net clinical outcomes using the TIMI‐AF score: Comparison with CHA2DS2‐VASc and HAS‐BLED , 2018, American heart journal.

[12]  G. Lip,et al.  Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA2DS2-VA Score Rather Than CHA2DS2-VASc? , 2018, Circulation.

[13]  L. Jordaens,et al.  Catheter Ablation for Atrial Fibrillation with Heart Failure , 2018, The New England journal of medicine.

[14]  J. Piccini,et al.  Association Between Left Atrial Appendage Occlusion and Readmission for Thromboembolism Among Patients With Atrial Fibrillation Undergoing Concomitant Cardiac Surgery , 2018, JAMA.

[15]  P. Noseworthy,et al.  Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. , 2017, Journal of the American College of Cardiology.

[16]  Michael B. Gravenor,et al.  Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study , 2017, Circulation.

[17]  G. Lip,et al.  Meta-Analysis of Effectiveness and Safety of Oral Anticoagulants in Atrial Fibrillation With Focus on Apixaban. , 2017, The American journal of cardiology.

[18]  S. Prabhu,et al.  Catheter Ablation Versus Medical Rate control in Atrial Fibrillation and Systolic Dysfunction (CAMERA-MRI) , 2017 .

[19]  A. Ferro,et al.  Indications for anticoagulant and antiplatelet combined therapy , 2017, British Medical Journal.

[20]  S. Kische,et al.  Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. , 2017, Heart rhythm.

[21]  Deepak L. Bhatt,et al.  Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation , 2017, The New England journal of medicine.

[22]  T. Steiner,et al.  Idarucizumab for Dabigatran Reversal — Full Cohort Analysis , 2017, The New England journal of medicine.

[23]  J. Saw,et al.  The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial. , 2017, American heart journal.

[24]  T. Mavrakanas,et al.  Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. , 2017, Journal of the American Society of Nephrology : JASN.

[25]  D. Singer,et al.  Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis , 2017, Journal of the American Heart Association.

[26]  L. Fleisher,et al.  2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2017, Journal of the American College of Cardiology.

[27]  J. Hartikainen,et al.  Sex, age, and time to cardioversion. Risk factors for cardioversion of acute atrial fibrillation from the FinCV study , 2017, Annals of medicine.

[28]  P. Noseworthy,et al.  Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study. , 2017, Gastroenterology.

[29]  K. Tellor,et al.  Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment , 2017, Pharmacotherapy.

[30]  C. Siu,et al.  Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation , 2017, JAMA.

[31]  D. Adams Idarucizumab for Dabigatran Reversal Full Cohort Analysis , 2017 .

[32]  S. Hohnloser,et al.  Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation , 2017, The New England journal of medicine.

[33]  R. de Caterina,et al.  Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. , 2017, Circulation.

[34]  J. Seward,et al.  Impact of Left Atrial Appendage Closure During Cardiac Surgery on the Occurrence of Early Postoperative Atrial Fibrillation, Stroke, and Mortality: A Propensity Score–Matched Analysis of 10 633 Patients , 2017, Circulation.

[35]  W. O’Neill,et al.  Post-Approval U.S. Experience With Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation. , 2017, Journal of the American College of Cardiology.

[36]  D. Singer,et al.  Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation , 2017, Circulation.

[37]  E. Antman,et al.  A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial , 2017, European heart journal.

[38]  Christopher X. Wong,et al.  Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions , 2016, European heart journal.

[39]  G. Lip,et al.  Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis , 2017, Stroke.

[40]  P. Noseworthy,et al.  Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. , 2016, Chest.

[41]  G. Lip,et al.  Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. , 2016, The New England journal of medicine.

[42]  Ya-Hui Hsueh,et al.  Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. , 2016, JAMA internal medicine.

[43]  G. Lip,et al.  Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin , 2016, Thrombosis and Haemostasis.

[44]  G. Lip,et al.  Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial , 2016, The Lancet.

[45]  L. Fauchier,et al.  Evaluation of 5 Prognostic Scores for Prediction of Stroke, Thromboembolic and Coronary Events, All-Cause Mortality, and Major Adverse Cardiac Events in Patients With Atrial Fibrillation and Coronary Stenting. , 2016, The American journal of cardiology.

[46]  S. Connolly,et al.  Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. , 2016, The New England journal of medicine.

[47]  S. Yusuf,et al.  Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). , 2016, Circulation.

[48]  M. Chung,et al.  Incidence of Thromboembolic Complications Within 30 Days of Electrical Cardioversion Performed Within 48 Hours of Atrial Fibrillation Onset. , 2016, JACC. Clinical electrophysiology.

[49]  L. Räber,et al.  Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention. , 2016, JACC. Cardiovascular interventions.

[50]  L. Fauchier,et al.  Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated? , 2016, Stroke.

[51]  G. Lip,et al.  Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study , 2016, British Medical Journal.

[52]  R. de Caterina,et al.  Cardioversion of Atrial Fibrillation in ENGAGE AF‐TIMI 48 , 2016, Clinical cardiology.

[53]  A. Phrommintikul,et al.  Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis , 2016, Open Heart.

[54]  P. Noseworthy,et al.  Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation , 2016, Journal of the American Heart Association.

[55]  C. Frost,et al.  Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis , 2016, Journal of clinical pharmacology.

[56]  Dhanunjaya R. Lakkireddy,et al.  Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial , 2016, Circulation.

[57]  William Smith,et al.  Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis , 2016, American Journal of Nephrology.

[58]  J. Cigarroa,et al.  Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, Circulation.

[59]  L. Biase Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions , 2016 .

[60]  L. Di Biase Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions , 2016, Journal of the American Heart Association.

[61]  S. Kische,et al.  Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry , 2016, European heart journal.

[62]  L. Fauchier,et al.  CHA2DS2-VASc Score for Predicting Stroke and Thromboembolism in Patients With AF and Biological Valve Prosthesis. , 2016, Journal of the American College of Cardiology.

[63]  S. Daher,et al.  The Complex Role of Anticoagulation in Cirrhosis: An Updated Review of Where We Are and Where We Are Going , 2016, Digestion.

[64]  E. Antman,et al.  Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial , 2015, Circulation.

[65]  J. Cigarroa,et al.  Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, Journal of the American College of Cardiology.

[66]  M. Price,et al.  Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience. , 2015, JACC. Cardiovascular interventions.

[67]  J. Messenger,et al.  Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. , 2015, JACC. Cardiovascular interventions.

[68]  S. Connolly,et al.  Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. , 2015, The New England journal of medicine.

[69]  Á. Avezum,et al.  Abstract 17277: Apixaban Use in Patients With Atrial Fibrillation With Bioprosthetic Valves: Insights From ARISTOTLE , 2015 .

[70]  A. Schjerning,et al.  Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin—A Nationwide Cohort Study , 2015, PloS one.

[71]  V. Hasselblad,et al.  Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. , 2015, The New England journal of medicine.

[72]  S. Hohnloser,et al.  Digoxin-associated mortality: a systematic review and meta-analysis of the literature. , 2015, European heart journal.

[73]  G. Lip,et al.  Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. , 2015, European heart journal.

[74]  D. De Bacquer,et al.  Dose-finding study of rivaroxaban in hemodialysis patients. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[75]  Saibal Kar,et al.  Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. , 2015, Journal of the American College of Cardiology.

[76]  M. Chung,et al.  Catheter Ablation for Atrial Fibrillation in Heart Failure Patients: A Meta-Analysis of Randomized Controlled Trials. , 2015, JACC. Clinical electrophysiology.

[77]  Christopher X. Wong,et al.  Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). , 2015, Journal of the American College of Cardiology.

[78]  H. Schunkert,et al.  Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. , 2015, Journal of the American College of Cardiology.

[79]  M. Gianni,et al.  Efficacy and safety of direct oral anticoagulants in patients undergoing cardioversion for atrial fibrillation: A systematic review and meta-analysis of the literature. , 2015, International journal of cardiology.

[80]  E. Edelman,et al.  Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis , 2015, Circulation.

[81]  S. Koul,et al.  Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. , 2015, Thrombosis research.

[82]  M. Lamberts,et al.  Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. , 2014, Journal of the American College of Cardiology.

[83]  A. Camm,et al.  Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. , 2014, European heart journal.

[84]  R. Mahajan,et al.  Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. , 2014, Journal of the American College of Cardiology.

[85]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[86]  G. Lip,et al.  Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. , 2014, QJM : monthly journal of the Association of Physicians.

[87]  S. Raposeiras-Roubín,et al.  Is 6-month GRACE risk score a useful tool to predict stroke after an acute coronary syndrome? , 2014, Open Heart.

[88]  Saibal Kar,et al.  Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. , 2014, JAMA.

[89]  I. Bryngelsson,et al.  Gender-related differences in risk of cardiovascular morbidity and all-cause mortality in patients hospitalized with incident atrial fibrillation without concomitant diseases: a nationwide cohort study of 9519 patients. , 2014, International journal of cardiology.

[90]  Eli N. Deal,et al.  Apixaban Use Among Patients With Severe Renal Impairment , 2014, The Annals of pharmacotherapy.

[91]  Donna K Arnett,et al.  AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and U.S. Department of Health and Human Services. , 2014, Journal of the American College of Cardiology.

[92]  Richard A. Goodman,et al.  AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and US Department of Health and Human Services. , 2014, Circulation.

[93]  Jeffrey L. Anderson,et al.  The Evolution and Future of ACC/AHA Clinical Practice Guidelines: A 30-Year Journey A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[94]  J. Hartikainen,et al.  Time to cardioversion for acute atrial fibrillation and thromboembolic complications. , 2014, JAMA.

[95]  M. Price,et al.  Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. , 2014, Journal of the American College of Cardiology.

[96]  Frank Beckers,et al.  Cryptogenic stroke and underlying atrial fibrillation. , 2014, The New England journal of medicine.

[97]  Thoralf M Sundt,et al.  2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.

[98]  Thoralf M Sundt,et al.  2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[99]  G. Fonarow,et al.  ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. , 2014, Circulation.

[100]  P. Kirchhof,et al.  One‐Year Outcome of Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting: An Analysis of the AFCAS Registry , 2014, Clinical cardiology.

[101]  Chad Hughes,et al.  Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. , 2014, The Journal of thoracic and cardiovascular surgery.

[102]  Jun Zhu,et al.  Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). , 2014, Journal of the American College of Cardiology.

[103]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[104]  F. Marchlinski,et al.  Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. , 2014, The American journal of cardiology.

[105]  Daniel E. Singer,et al.  Device-detected atrial fibrillation and risk for stroke: an analysis of >10 000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices) , 2013, European heart journal.

[106]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[107]  L. Shaw,et al.  ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.

[108]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[109]  W. Abhayaratna,et al.  Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. , 2013, JAMA.

[110]  S. Connolly,et al.  Dabigatran versus warfarin in patients with mechanical heart valves. , 2013, The New England journal of medicine.

[111]  J. Hartikainen,et al.  Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. , 2013, Journal of the American College of Cardiology.

[112]  L. Køber,et al.  Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. , 2013, Journal of the American College of Cardiology.

[113]  Petr Neuzil,et al.  Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). , 2013, Journal of the American College of Cardiology.

[114]  A. Kastrati,et al.  Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. , 2013, Journal of the American College of Cardiology.

[115]  G. Breithardt,et al.  Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. , 2013, Journal of the American College of Cardiology.

[116]  Tom Adriaenssens,et al.  Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial , 2013, The Lancet.

[117]  Deepak L. Bhatt,et al.  ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[118]  Deepak L. Bhatt,et al.  ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[119]  PubMed Id ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013 .

[120]  Yuan Zhang,et al.  Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation. , 2013, Heart rhythm.

[121]  Gregory Y H Lip,et al.  New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation , 2012, Expert review of cardiovascular therapy.

[122]  A. Brand,et al.  Is female sex a risk factor for red blood cell alloimmunization after transfusion? A systematic review. , 2012, Transfusion medicine reviews.

[123]  J. Olesen,et al.  Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study , 2012, Journal of thrombosis and haemostasis : JTH.

[124]  T. Lehr,et al.  Dabigatran Etexilate in Atrial Fibrillation Patients With Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation , 2012, Journal of clinical pharmacology.

[125]  Habib Gamra,et al.  Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical Practice: Insight From the Real-Life Global Survey Evaluating Patients With Atrial Fibrillation International Registry , 2012, Circulation. Arrhythmia and electrophysiology.

[126]  S. Connolly,et al.  A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). , 2012, American heart journal.

[127]  D. Lake,et al.  Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. , 2012, The American journal of medicine.

[128]  J. Olesen,et al.  The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: A nationwide cohort study , 2012, Thrombosis and Haemostasis.

[129]  Salim Yusuf,et al.  Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study. , 2012, Journal of the American College of Cardiology.

[130]  D. Singer,et al.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[131]  A. Capucci,et al.  Subclinical atrial fibrillation and the risk of stroke. , 2012, The New England journal of medicine.

[132]  S. Hariharan,et al.  Clinical Pharmacology Basis of Deriving Dosing Recommendations for Dabigatran in Patients With Severe Renal Impairment , 2012, Journal of clinical pharmacology.

[133]  Shigeto Miura,et al.  [Hemodialysis patients]. , 2012, Nihon rinsho. Japanese journal of clinical medicine.

[134]  A. Mills,et al.  Is discharge to home after emergency department cardioversion safe for the treatment of recent-onset atrial fibrillation? , 2011, Annals of emergency medicine.

[135]  W. Winkelmayer,et al.  Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[136]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[137]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[138]  Prashanthan Sanders,et al.  Pericardial fat is associated with atrial fibrillation severity and ablation outcome. , 2011, Journal of the American College of Cardiology.

[139]  Jun Zhu,et al.  Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[140]  S. Yusuf,et al.  Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion , 2010, Circulation.

[141]  S. Greenfield,et al.  Clinical practice guidelines we can trust , 2011 .

[142]  Laura A. Levit,et al.  Finding what works in health care : standards for systematic reviews , 2011 .

[143]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[144]  P. Lavori,et al.  Effect of home testing of international normalized ratio on clinical events. , 2010, The New England journal of medicine.

[145]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[146]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[147]  S. Schneider,et al.  Prevalence of left atrial thrombus and dense spontaneous echo contrast in patients with short-term atrial fibrillation < 48 hours undergoing cardioversion: value of transesophageal echocardiography to guide cardioversion. , 2009, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[148]  P. Komenda,et al.  The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis? , 2009, Chest.

[149]  Dongfeng Qi,et al.  The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study , 2009, Circulation. Arrhythmia and electrophysiology.

[150]  Salim Yusuf,et al.  Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[151]  Jacky Serveille,et al.  [Ablation of atrial fibrillation]. , 2008, Soins; la revue de reference infirmiere.

[152]  Eva Navas,et al.  Accepted Manuscript , 2022 .

[153]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[154]  S. Hohnloser,et al.  Prevention of stroke in patients with atrial fibrillation: Current strategies and future directions , 2008 .

[155]  D. Singer,et al.  Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study , 2005, Circulation.

[156]  M. Aguilar,et al.  Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. , 2005, The Cochrane database of systematic reviews.

[157]  J. McMurray,et al.  Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. , 2005, Journal of the American College of Cardiology.

[158]  R. Bergemann,et al.  Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation Study. , 2005, Chest.

[159]  D. Parish,et al.  Obesity and the risk of new-onset atrial fibrillation. , 2005, JAMA.

[160]  G. Lamas,et al.  Atrial High Rate Episodes Detected by Pacemaker Diagnostics Predict Death and Stroke: Report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST) , 2003, Circulation.

[161]  G. Lip,et al.  Antithrombotic therapy for atrial fibrillation , 2002, BMJ : British Medical Journal.

[162]  C. M. Hart,et al.  Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. , 2002, Journal of the American College of Cardiology.

[163]  J. Halperin,et al.  Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. , 2001, The New England journal of medicine.

[164]  J. Thomas,et al.  Efficacy of anticoagulation in resolving left atrial and left atrial appendage thrombi: A transesophageal echocardiographic study. , 2000, American heart journal.

[165]  K A Schulman,et al.  Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. , 2000, Circulation.

[166]  L. Køber,et al.  The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. , 1999, European heart journal.

[167]  M. Ezekowitz,et al.  Initiating and Maintaining Patients on Warfarin Anticoagulation: The Importance of Monitoring , 1999, Journal of cardiovascular pharmacology and therapeutics.

[168]  J. Wootton Clinical practice guidelines. , 1999, Journal of women's health & gender-based medicine.

[169]  R. Califf,et al.  Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. , 1997, Journal of the American College of Cardiology.

[170]  B. Iung,et al.  AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. , 1996, Circulation.

[171]  J. Vandenbroucke,et al.  Optimal oral anticoagulant therapy in patients with mechanical heart valves. , 1995, The New England journal of medicine.

[172]  V. Fuster,et al.  Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association. , 1994, Circulation.

[173]  U. Goldbourt,et al.  Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction , 1992 .

[174]  U. Goldbourt,et al.  Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction. SPRINT Study Group. , 1992, European heart journal.

[175]  J. Alpert,et al.  Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective. , 1990, American heart journal.

[176]  G. Bennett,et al.  The assessment. , 1989, Health visitor.

[177]  J. G. Sharnoff Prevention of thromboembolism. , 1963 .